1：Experimental Design and Method Selection:

C60 nanoparticles were prepared by grinding C60 with sugammadex or γ-cyclodextrin using an automatic magnetic agitating mortar, followed by dispersion in water or PBS via ultrasonication. Characterization included dynamic light scattering for particle size and zeta potential measurements. Aggregation behavior was studied in various salt solutions. Biodistribution studies were conducted in tumor-bearing mice after intravenous administration, with C60 extraction from organs and blood using HPLC. Photodynamic activity was evaluated in vitro using ESR spectrometry and cell viability assays, and in vivo by monitoring tumor growth after light irradiation.

2：Sample Selection and Data Sources:

C60 and C70 were purchased from Frontier Carbon Co.; sugammadex from MSD K.K.; γ-CD from Nihon Shokuhin Kako Co. Mouse sarcoma S-180 cells were used in tumor models implanted in ddY mice.

3：List of Experimental Equipment and Materials:

Automatic magnetic agitating mortar (MNV-01, AS ONE), dynamic light scattering instrument (DLS-8000HL, Otsuka Electronics), zeta potential analyzer (ELS-Z, Otsuka Electronics), HPLC system (Hitachi), xenon light source (MAX-303, Asahi Spectra), ESR spectrometer, and various chemicals like NaCl, KCl, CaCl2, MgCl2, PBS, etc.

4：Experimental Procedures and Operational Workflow:

Grinding C60 with CDs for 3 hours at 4°C under reduced pressure, dispersion by ultrasonication, measurement of particle size and zeta potential, addition of salt solutions to study aggregation, intravenous injection in mice, organ extraction and HPLC analysis, light irradiation for PDT, and statistical analysis using t-tests.

5：Data Analysis Methods:

Data were analyzed using student's t-tests for significance, with p < 0.05 considered significant. Pharmacokinetic parameters were calculated from plasma concentration data.